Dosage d'Oxaliplatine pour les patients adultes atteints de cancer présentant une fonction rénale altérée
Cette étude vise à déterminer le dosage approprié de l'Oxaliplatine pour les patients adultes atteints de cancer présentant une fonction rénale altérée, en se concentrant sur sa sécurité et son efficacité dans le traitement.
Oxaliplatin
Maladies génito-urinaires+13
+ Maladies urogénitales féminines et complications de la grossesse
+ Néoplasmes par site
Étude thérapeutique
Résumé
Date de début de l'étude : 1 septembre 1999
Date à laquelle le premier participant a commencé l'étude.Oxaliplatin is a diaminocyclohexane platinum derivative with known anticancer activity in solid tumors. The recommended single-agent dose of Oxaliplatin in adult cancer patients with normal renal function is 130 mg/m(2) given intravenously over 2 hours every 3 weeks. Renal excretion is thought to be the major route of drug elimination, but precise dosing guidelines in patients with abnormal renal function have not been determined. This phase I and pharmacologic study of single agent Oxaliplatin is being conducted in adult cancer patients with impaired renal function. Patients will be stratified into four groups based upon their degree of renal impairment as assessed by a 24 hour creatinine clearance. Group A will consist of 12 patients with normal renal function who will serve as pharmacologic controls. The remaining 3 groups will start at different doses of Oxaliplatin based upon their degree of renal dysfunction and dose escalation in these groups will proceed in a manner in accordance with standard phase I trials with 3 patients per dose level until dose limiting toxicity is observed. Pharmacokinetic monitoring will be performed in all patients on study. The goals of this trial are to define the toxicities and pharmacokinetics of single agent Oxaliplatin in this patient population and to determine recommended doses of Oxaliplatin in patient with different degrees of renal dysfunction.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.60 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Patients must have histologically confirmed malignancy which is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Patients with prior chemotherapy, radiation therapy, hormonal therapy and immunotherapy are allowed with the exception that patients cannot have had prior treatment with oxaliplatin. Patients greater than or equal to 18 years of age. Patients must have an ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60 percent) and a life expectancy of at least 3 months. Patients must have adequate organ and marrow function which includes: Leukocytes must be greater than or equal to 3,000/microliter. Absolute neutrophil count must be greater than or equal to 1,500/microliter. Platelet count must be greater than or equal to 100,000/microliter. Total bilirubin within normal institutional limits. AST (SGOT)/ALT(SGPT) less than or equal to 1.5 times the upper limit of normal. Patients with no evidence of clinically significant neuropathy. Women of child-bearing potential and men must agree to use adequate contraception. Patients must have the ability to understand and the willingness to sign a written informed consent document. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study, or within 6 weeks of prior platinum therapy will be excluded. Patients undergoing therapy with other investigational agents will be excluded. Patients with known brain metastaseswill be excluded. Patients with a history of an allergy to platinum compounds will be excluded. Patients with uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, or unstable angina pectoris, or cardiac arrhythmia will be excluded. Women must not be pregnant or nursing. Patients must not be HIV-positive or receiving anti-retroviral therapy (HAART). Patients actively receiving renal dialysis treatments while on the study will be excluded.
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 1 site
National Cancer Institute (NCI)
Bethesda, United StatesOuvrir National Cancer Institute (NCI) dans Google Maps